A Phase 4 interventional study of 20-valent pneumococcal conjugate vaccine in Alpha 1-Antitrypsin, COPD and Antibody Deficiency, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by University of Alabama at Birmingham · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States — 17 open to participants now, 22 under way, 5 of them phase 3. alpha 1-Antitrypsin Deficiency · United States.
Among the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, this one is the 28th largest by planned enrollment of the 55 interventional ones that give a count, is one of 4 that started in 2025, is one of 4 in phase 4, reaches primary completion later than 3 of the 20 other live ones, and was the 78th registered.
142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.
Browse alpha 1-Antitrypsin Deficiency studies →17 of the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States are open now. Recruiting first, the newest first:
Grifols Therapeutics LLC · Sites in United States, Denmark, Germany and 6 more countries
Ages 18–80
Tessera Therapeutics, Inc. · Sites in United States, Australia, Netherlands and 2 more countries
Ages 18–70
Columbia University · Sites in United States
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 18–70
Takeda · Sites in United States, Austria, Germany and 3 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 28 · Phase 3 11 · Phase 4 4
First in 1995; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is close to the median of 33 across 86 interventional studies indexed under alpha 1-Antitrypsin Deficiency.
Median enrollment 30 across the 55 interventional studies, 190 across the 26 observational. Of the 57 that completed or were terminated, 29 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 81 have an industry lead sponsor. The 10 most frequent:
University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
University of Alabama at Birmingham has 2 studies filed under alpha 1-Antitrypsin Deficiency — fewer than ten, so there is no comparison to draw.
3 of the studies in alpha 1-Antitrypsin Deficiency with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT05297812Columbia UniversityAlpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease | 2027-01 |
| NCT07135427University of Alabama at BirminghamGenetic Variation in IgG in Alpha 1 Antitrypsin Deficiency | 2027-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections.
To investigate this hypothesis, we will compare immune responses to the 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer) between participants who have one abnormal copy of the SERPINA1 gene and either no COPD exacerbations, vs those with 2 or more COPD exacerbations in the past year.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who are heterozygous for the SERPINA1 'Z' allele with either 0 or 2+ exacerbations in the previous year, and have not received pneumococcal vaccination within 5 years will be given PCV20.
Biological: 20-valent pneumococcal conjugate vaccine
Administration of PCV20
Antibody response
Pneumococcal antibody levels/function, total IgG levels, IgG subclass levels; magnitude of change from baseline
Time frame: 4 weeks from baseline measurement
Lymphocyte profile
B and T cell lymphocyte subsets
Time frame: Baseline, 4 weeks post-vaccination
Gene variants
Variants in SERPINA1, IGHG genes
Time frame: Baseline
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Mar 2027, 18 months after the start.
Completion moved once since we started tracking on Sep 25, 2026: Jun 2027 → Sep 2027, on Oct 27, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine
alpha 1-Antitrypsin Deficiency →
University of Alabama at Birmingham →